Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice
November 2025: FDA approved expanded Zepbound (tirzepatide) indication for moderate-to-severe obstructive sleep apnea in adults with obesity, following SURMOUNT-OSA trial data showing 62.8% reduction in apnea-hypopnea index the first drug approval for sleep apnea treatment
TGF: transforming growth factor
Bastin M, Andreelli F
Further, the mechanisms underlying long COVID are not fully understood, which hamper efficient treatment options
US$ 29.39
US$ 27.45
US$ 27.83
US$ 22.55
US$ 25.41
